Literature DB >> 9743348

Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents.

S K Manna1, B B Aggarwal.   

Abstract

Alpha-melanocyte-stimulating hormone (alpha-MSH) is a tridecapeptide found mainly in the brain, pituitary, and circulation. It inhibits most forms of inflammation by a mechanism that is not known. As most types of inflammation require activation of NF-kappa B, we investigated the effect of alpha-MSH on the activation of this transcription factor by a wide variety of inflammatory stimuli. Electrophoretic mobility shift assay showed that alpha-MSH completely abolished TNF-mediated NF-kappa B activation in a dose- and time-dependent manner. It also suppressed NF-kappa B activation induced by LPS, okadaic acid, and ceramide. The effect was specific, as the activation of the transcription factor activating protein-1 by TNF was unaffected. Western blot analysis revealed that TNF-dependent degradation of the inhibitory subunit of NF-kappa B, I kappa B alpha, and nuclear translocation of the p65 subunit of NF-kappa B were also inhibited. This correlated with suppression of NF-kappa B-dependent reporter gene expression induced by TNF. The inhibitory effect of alpha-MSH appeared to be mediated through generation of cAMP, as inhibitors of adenylate cyclase and of protein kinase A reversed its inhibitory effect. Similarly, addition of membrane-permeable dibutyryl cAMP, like alpha-MSH, suppressed TNF-induced NF-kappa B activation. Overall, our results suggest that alpha-MSH suppresses NF-kappa B activated by various inflammatory agents and that this mechanism probably contributes to its anti-inflammatory effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9743348

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  59 in total

1.  MC(1) receptors are constitutively expressed on leucocyte subpopulations with antigen presenting and cytotoxic functions.

Authors:  G Neumann Andersen; O Nagaeva; I Mandrika; R Petrovska; R Muceniece; L Mincheva-Nilsson; J E Wikberg
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

Review 2.  MC1R, eumelanin and pheomelanin: their role in determining the susceptibility to skin cancer.

Authors:  Tahseen H Nasti; Laura Timares
Journal:  Photochem Photobiol       Date:  2014-11-07       Impact factor: 3.421

3.  The biphasic immunoregulation of pyrimidylpiperazine (Y-40138) is IL-10 sensitive and requires NF-kappa B targeting in the alveolar epithelium.

Authors:  J J Haddad; B Safieh-Garabedian; N E Saadé; S C Land
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

4.  Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults.

Authors:  Pierre A Robe; Didier H Martin; Minh T Nguyen-Khac; Maria Artesi; Manuel Deprez; Adelin Albert; Sophie Vanbelle; Stephane Califice; Markus Bredel; Vincent Bours
Journal:  BMC Cancer       Date:  2009-10-19       Impact factor: 4.430

5.  Both MC5r and A2Ar are required for protective regulatory immunity in the spleen of post-experimental autoimmune uveitis in mice.

Authors:  Darren J Lee; Andrew W Taylor
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

Review 6.  [Alpha-melanocyte-stimulating hormone. Its current significance for dermatology].

Authors:  M Böhm; T A Luger
Journal:  Hautarzt       Date:  2004-05       Impact factor: 0.751

7.  Diminishment of alpha-MSH anti-inflammatory activity in MC1r siRNA-transfected RAW264.7 macrophages.

Authors:  Dayu Li; Andrew W Taylor
Journal:  J Leukoc Biol       Date:  2008-04-03       Impact factor: 4.962

8.  The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans.

Authors:  Karin Loser; Thomas Brzoska; Vinzenz Oji; Matteo Auriemma; Maik Voskort; Verena Kupas; Lars Klenner; Cornelius Mensing; Axel Hauschild; Stefan Beissert; Thomas A Luger
Journal:  PLoS One       Date:  2010-02-01       Impact factor: 3.240

9.  Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment.

Authors:  B Shariat-Madar; D Kolte; A Verlangieri; Z Shariat-Madar
Journal:  Diabetes Metab Syndr Obes       Date:  2010-04       Impact factor: 3.168

10.  Inflamed phenotype of the mesenteric microcirculation of melanocortin type 3 receptor-null mice after ischemia-reperfusion.

Authors:  Giovanna Leoni; Hetal B Patel; André L F Sampaio; Felicity N E Gavins; Joanne F Murray; Paolo Grieco; Stephen J Getting; Mauro Perretti
Journal:  FASEB J       Date:  2008-08-29       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.